MacroGenics, Inc.

Macrogenics Inc. is a biopharmaceutical company dedicated to creating and developing innovative protein-based therapeutics for the treatment of cancer. The core of its operations involves the discovery and engineering of monoclonal antibodies and bispecific molecules aimed at targeting specific proteins involved in cancer growth and proliferation. A notable feature of Macrogenics is their proprietary technology platforms, such as the Dual-Affinity Re-Targeting (DART) platform, which is pivotal in developing multispecific antibodies designed to manage diverse types of cancer more effectively. The company’s research pipeline includes a variety of investigational and clinical programs, many of which are partnerships with other pharmaceutical companies, underscoring its significant role in advancing cancer research. Founded in 2000 and headquartered in the United States, Macrogenics contributes to the biopharmaceutical industry by driving forward novel cancer treatments through precision and targeted therapies. Its work has implications across both the healthcare sector, focusing primarily on oncology, and the broader medical research community, enhancing the potential for personalized medicine in cancer care.